ASAT1 Antibody

Potential Association with ASS1 in Cancer Biology

ASS1 (Argininosuccinate Synthase 1) is a urea cycle enzyme that catalyzes the synthesis of argininosuccinate from citrulline and aspartate. Recent studies highlight its antitumor role in triple-negative breast cancer (TNBC):

• Mechanism: ASS1 binds to PHGDH (phosphoglycerate dehydrogenase), promoting its ubiquitination-mediated degradation. This suppresses serine synthesis, critical for cancer proliferation ( ).

• Therapeutic Antibody Implications:

  • ASS1 loss correlates with poor prognosis in cancers.

  • Antibodies targeting ASS1-associated pathways (e.g., PHGDH inhibitors) are under investigation.

Key Findings from ASS1 Research

ASGR1 Antibody in Viral Infection

Asialoglycoprotein Receptor 1 (ASGR1) is a hepatic receptor studied for its role in SARS-CoV-2 entry:

• Function: ASGR1 facilitates SARS-CoV-2 pseudovirus infection in hepatocytes independent of ACE2 ( ).

• Antibody Applications:

  • Anti-ASGR1 antibodies block viral entry in vitro.

  • siRNA targeting ASGR1 reduces infection rates in hepatic cells.

ASGR1 Antibody Experimental Data

General Antibody Structure and Function

While not specific to ASAT1, foundational antibody biology informs its potential applications:

• Structure: Y-shaped glycoproteins with variable (antigen-binding) and constant (effector function) regions ( ).

• Functional Mechanisms:

  • Neutralization (e.g., blocking viral receptors).

  • Opsonization (e.g., marking pathogens for phagocytosis).

  • Complement activation (e.g., inducing pathogen lysis) ( ).

Antibody Engineering Trends

Research Gaps and Future Directions

• ASAT1 Clarification: The term "ASAT1" is not defined in current literature; potential typographical errors (e.g., ASS1, ASGR1) require verification.

• Therapeutic Development: Antibodies targeting metabolic enzymes (e.g., ASS1) or viral entry receptors (e.g., ASGR1) represent emerging frontiers in oncology and virology.